Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., China, for the commercialisation of two insulin analogues in India. The partnership, announced on August 20, 2026, grants Mankind Pharma exclusive rights to market Insulin Degludec and the Insulin Degludec + Aspart combination.

Deal highlights

The licensing arrangement expands Mankind Pharma’s presence in the diabetes segment by adding advanced injectable therapies to its existing portfolio. The key details of the agreement are as follows:

Strategic significance

Insulin Degludec is a long-acting basal insulin used in diabetes management, while the Insulin Degludec + Aspart combination addresses both basal and mealtime insulin requirements. By securing exclusive rights to both formulations, Mankind Pharma broadens its offering across the insulin therapy spectrum in India.

Atish Majumdar, Senior President – Sales and Marketing at Mankind Pharma Ltd., highlighted the strategic importance of the partnership. He noted that China is rapidly emerging as a hub for innovative biopharmaceutical assets. Building on previous partnerships for Insulin Aspart and Insulin Degludec, the company remains focused on expanding its in-licensing pipeline from China to bring advanced therapies to patients in India.

Broader context

The partnership aligns with Mankind Pharma’s strategy of leveraging global innovation through strategic partnerships. China’s developing biopharmaceutical ecosystem offers opportunities for Indian pharmaceutical companies to access differentiated assets that complement their existing portfolios. This move reinforces the company’s commitment to addressing the evolving needs of patients in the injectable diabetes segment.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE634S01028/491591c1-eab2-4bfa-8412-79106d6397d5.pdf

Mankind Pharma Limited has initiated the process to appoint Anish Vanraj Bafna as a non-executive independent director, dispatching a postal ballot notice to shareholders on August 18, 2026. The company seeks approval via a special resolution through remote e-voting for Bafna’s appointment for a term of five consecutive years, effective from August 10, 2026.

The Board of Directors approved the appointment following a recommendation from the Nomination and Remuneration Committee. Bafna, who holds DIN 02925792, was initially appointed as an additional director designated as an independent director under Section 161 of the Companies Act, 2013. His final appointment is subject to shareholder ratification through the postal ballot mechanism mandated by Regulation 44 of the SEBI Listing Regulations.

E-Voting Timeline and Procedure

Shareholders whose names appear in the register of members or beneficial owners as of the cut-off date, August 14, 2026, are eligible to vote. The remote e-voting facility, facilitated by National Securities Depository Limited (NSDL), operates within the following timeline:

The voting results, along with the scrutinizer’s report from Neelesh Kumar Jain of N.K.J. & Associates, will be uploaded to the company’s website and stock exchanges within two working days of the voting conclusion.

Director Profile and Qualifications

Anish Vanraj Bafna brings over three decades of experience in the healthcare and medical devices sector. He previously served as Chief Executive Officer and Managing Director of Healthium Medtech Limited for more than eight years and currently holds the position of Non-Executive Chairman there. Prior to his tenure at Healthium, Bafna worked with Baxter International, serving as President for Japan and Regional Head for Emerging Asia, overseeing operations across India and Southeast Asia.

Bafna holds a Bachelor of Science degree in Chemistry from St. Xavier’s, Ahmedabad, and a Post Graduate Diploma in Management from IMDR, Pune. He has confirmed his independence under Section 149(6) of the Companies Act and Regulation 16(1)(b) of the Listing Regulations. Additionally, he is registered in the Independent Directors’ Databank maintained by the Indian Institute of Corporate Affairs.

Remuneration and Terms

As an independent director, Bafna will not be liable to retire by rotation. His remuneration structure includes sitting fees for attending board or committee meetings, reimbursement of expenses incurred for participation, and profit-related commission. These terms are subject to the limits prescribed under Sections 197 and 198 of the Companies Act, 2013, and applicable listing regulations. The board retains the authority to determine specific fee rates from time to time.

What the Numbers Show

The appointment introduces significant international healthcare management experience to the board without altering the promoter-controlled ownership structure. Bafna holds nil shareholding in Mankind Pharma as of the postal ballot notice date, ensuring his independence from financial interests in the company while contributing strategic oversight from his background in global medical device operations.